Segmentation by type isolates the chemical and processing variants of CLA powder that influence both functional performance and market valuation. The cis‑9, trans‑11 isomer remains the most prevalent, representing about 45 % of volume due to its superior safety profile and documented anti‑obesity efficacy. The trans‑10, cis‑12 isomer, comprising roughly 20 % of supply, is valued for its role in body‑fat reduction and insulin‑sensitivity modulation, attracting premium pricing in niche formulations. Mixed‑isomer blends, which combine the two major isomers in balanced ratios, hold a 25 % share, offering manufacturers a versatile ingredient for broad‑spectrum health claims. A smaller yet growing niche, microencapsulated CLA, accounts for the remaining 10 % and is distinguished by enhanced oxidative stability and controlled release, enabling incorporation into liquid beverages and heat‑processed foods. These type‑specific attributes directly affect cost structures, regulatory classification, and end‑use suitability, thereby delineating the market taxonomy for Conjugated Linoleic Acid Powder.